Novel Advanced Prostate Cancer Drug Shows Promise In Early Tests

Results of early tests on a novel experimental prostate cancer drug bring hope to men diagnosed with the most aggressive form of the disease that resists current treatments. The findings of early phase I/II trials of the drug, dubbed MDV3100 and made by San Francisco-based Medivation Inc, are to be published later this week in the journal Science in a study led by Charles Sawyers of Memorial Sloan-Kettering Cancer Center in New York.

More: continued here

Filed under: Cancer on April 10th, 2009